GMED vs LQDA
Globus Medical vs Liquidia Corporation — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
LQDA
Liquidia Corporation
68
Buy
| Metric | GMED | LQDA |
|---|
| AI Score |
71
|
68
|
| Price |
$85.12
|
$88.09
|
| P/E Ratio |
21.45×
|
368.26×
|
| ROE |
11.8%
|
-154.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
91.8%
|
| Debt / Equity |
0.02×
|
1.70×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
55.0
|
| Beta |
0.954
|
0.572
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus LQDA.
GMED leads by 3 points.
GMED scores 71/100 (Buy) versus LQDA at 68/100 (Buy).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical